The share acquisitions announced by Orion Corporation on 23 April 2013 have been completed. The Company has purchased during the time period from 22 November 2013 to 11 December 2013 through public trading in accordance with the rules of on the NASDAQ OMX Helsinki Ltd. a total of 500,000 Company's own B shares at an average price per share of approximately EUR 19.22. The total purchase price paid for the shares was EUR 9,611,985.00.
After the repurchases, the Company holds a total of 688,991 own B shares corresponding to approximately 0.48% of the total number of the shares and 0.07% of the votes.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.